Review of psychedelic therapy options for PTSD

This review published in the Journal of Neuropsychology explores the potential of psychedelic therapies for PTSD.

4 types of compounds are discussed: MDMA, ketamine, classical psychedelics (e.g., psilocybin and LSD), and cannabinoids. For each compound, evidence is collated on:

  1. The background/ a brief history
  2. The therapeutic rationale
  3. The setting in which they are normally given
  4. Route of administration and dosage
  5. State of evidence in the treatment of PTSD
  6. Safety and potential side effects.

The authors conclude that "each compound provides unique qualities for the treatment of PTSD, from their use to rapidly target symptoms to their use as adjuncts to facilitate psychotherapeutic treatments". An outline for future research for psychedelic therapies for PTSD is also proposed.

For more emerging research on all things psychedelic, visit the psychedelic network website.

Previous
Previous

Psychedelic microdosing - 'largest placebo-controlled trial on psychedelics to-date'.

Next
Next

Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial.